BIOLASE Announces Delisting from Nasdaq
BIOLASE, a leader in dental lasers, announced its delisting from Nasdaq due to non-compliance with listing requirements, such as maintaining a $1.00 minimum bid price and $2.5 million in stockholders' equity. Trading on Nasdaq will halt on June 20, 2024. CEO John Beaver emphasized that despite this setback, BIOLASE remains committed to expanding laser adoption in dental care. The company's stock will start trading on the OTC Markets Group platform under the symbol "BIOL" and aims to move to the OTCQB Market shortly.
- None.
- Delisting from Nasdaq due to non-compliance with listing requirements.
- Failure to meet $1.00 minimum bid price.
- Failure to maintain $2,500,000 minimum stockholders' equity.
Insights
The delisting of BIOLASE from Nasdaq presents significant **financial implications** for stakeholders. When a company is delisted, it often experiences a **drop in liquidity** and a potential decrease in stock price due to reduced visibility and investor interest. The move to OTC Markets is typically seen as a step down from Nasdaq, which can impact investor confidence.
From a financial standpoint, the **failure to meet Nasdaq's listing requirements**—specifically, the $1.00 minimum bid price and $2,500,000 minimum stockholders' equity—signals underlying issues. These metrics are fundamental thresholds that reflect a company's market perception and financial health. Not meeting them indicates that BIOLASE might be struggling financially or facing operational challenges that hinder its ability to maintain these minimum standards.
**Investors should consider** the potential for continued volatility in the stock price. Trading on OTC Markets can introduce higher volatility due to generally lower volume and fewer regulatory requirements. Additionally, the company will face challenges in regaining trust and attracting new investment without the prestige and oversight associated with Nasdaq.
For a retail investor, understanding the **market dynamics** post-delisting is critical. **OTC Markets**, while accessible, do not provide the same level of prestige or oversight as Nasdaq. This shift often results in **reduced analyst coverage** and **lower institutional investment**, both of which can contribute to a decline in stock price and market capitalization.
BIOLASE's CEO mentions the **untapped potential** in the dental market, which is a positive long-term indicator. However, the immediate impact of this delisting is more pressing. The dental market is indeed large, but adoption of new technology like laser-based dental equipment can be slow and requires substantial marketing and educational efforts to convince practitioners to change their methods.
**Investors should temper expectations** for a quick turnaround. The delisting reflects current market reality and operational challenges. While there may be long-term growth potential, the near-term focus should be on how the company manages this transition and addresses underlying financial issues.
LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the
BIOLASE CEO John Beaver. commented, "While we are disappointed in the Nasdaq delisting, this does not deter us from our long-term strategy of accelerating the adoption of lasers as we believe they will become the gold standard of dental care. There remains a significant untapped opportunity in the dental market for our BIOLASE lasers, with more than
The Company expects its common stock to commence trading on the OTC Markets Group platform at the open of trading on June 20, 2024, under the symbol "BIOL." The Company has applied to trade its common stock on the OTCQB Market and expects to commence trading of its common stock on the OTCQB in the coming days.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 patented and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology and include statements such as the expected commencement of trading of the Company's common stock on the OTC Markets Group platform at the open of trading on June 20, 2024, under the symbol "BIOL", the expected commencement of trading on the OTCQB in the coming days and transforming BIOLASE into the leading dental laser company in the world the Company has applied to trade on the OTCQB Market. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the ability of the Company to commence trading of its common stock on the OTCQB and those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's Annual Report filed on Form 10-K filed with the SEC and other filings by BIOLASE with the SEC. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Investor Relations:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
SOURCE: BIOLASE, Inc.
View the original press release on accesswire.com
FAQ
Why is BIOLASE being delisted from Nasdaq?
When will BIOLASE be delisted from Nasdaq?
What will happen to BIOLASE stock after delisting from Nasdaq?
What is the new trading symbol for BIOLASE after delisting?
Is BIOLASE planning to list on another market after Nasdaq delisting?
